Info

🌱 來自: Metastatic Colon Cancer

BRiTE

Bevacizumab Beyond First Progression is → Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) | Journal of Clinical Oncology

1. Design: observational, bevacizumab treatment study (Bevacizumab Regimens: Investigation of Treatment Effects and Safety [BRiTE]), single-center, not randomized, open-label.
2. Number of patients: 1,445 patients with mCRC who experienced disease progression were analyzed.
3. Patients characteristics: previously untreated patients with mCRC who were enrolled in BRiTE and who experienced disease progression (PD).
4. Agent: Bevacizumab was used in this trial.
5. Treatment line: Beyond first progression treatment with Bevacizumab.
6. Trial Name/NCT Number: Bevacizumab Regimens: Investigation of Treatment Effects and Safety [BRiTE] (NCT00203627).
7. Comparison of two groups in a markdown table:

Group/Outcome	No post-PD	No BBP	BBP
Median OS	12.6 months	19.9 months	31.8 months
HR (vs No BBP)	Not reported	0.48	Not reported
P value	Not reported	< .001	Not reported
Hypertension that required medication	Not reported	19.2%	24.6%

Note: HR = Hazard Ratio, PFS not reported.